{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:20:51Z","timestamp":1793226051031,"version":"4.5.0"},"reference-count":196,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T00:00:00Z","timestamp":1528761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s40272-018-0297-x","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T02:27:08Z","timestamp":1528770428000},"page":"395-408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Pediatric Cancer Immunotherapy: Opportunities and Challenges"],"prefix":"10.1007","volume":"20","author":[{"given":"Mary Frances","family":"Wedekind","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas L.","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Cripe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,12]]},"reference":[{"issue":"3","key":"297_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/00000658-189112000-00015","volume":"14","author":"WB Coley II","year":"1891","unstructured":"Coley WB II. Contribution to the knowledge of sarcoma. Ann Surg. 1891;14(3):199\u2013220.","journal-title":"Ann Surg"},{"key":"297_CR2","first-page":"154","volume":"26","author":"EF McCarthy","year":"2006","unstructured":"McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006;26:154\u20138.","journal-title":"Iowa Orthop J"},{"key":"297_CR3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00003086-199101000-00002","volume":"262","author":"WB Coley","year":"1991","unstructured":"Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res. 1991;262:3\u201311.","journal-title":"Clin Orthop Relat Res"},{"key":"297_CR4","first-page":"1","volume":"276","author":"HC Nauts","year":"1953","unstructured":"Nauts HC, Fowler GA, Bogatko FH. A review of the influence of bacterial infection and of bacterial products (Coley\u2019s toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley\u2019s mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med Scand Suppl. 1953;276:1\u2013103.","journal-title":"Acta Med Scand Suppl"},{"key":"297_CR5","doi-asserted-by":"publisher","first-page":"820813","DOI":"10.1155\/2015\/820813","volume":"2015","author":"T Uehara","year":"2015","unstructured":"Uehara T, et al. Immunotherapy for bone and soft tissue sarcomas. Biomed Res Int. 2015;2015:820813.","journal-title":"Biomed Res Int"},{"issue":"5023","key":"297_CR6","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/bmj.1.5023.841","volume":"1","author":"M Burnet","year":"1957","unstructured":"Burnet M. Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J. 1957;1(5023):841\u20137.","journal-title":"Br Med J"},{"key":"297_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fonc.2015.00181","volume":"5","author":"SS Roberts","year":"2015","unstructured":"Roberts SS, Chou AJ, Cheung NK. Immunotherapy of childhood sarcomas. Front Oncol. 2015;5:181.","journal-title":"Front Oncol"},{"issue":"6","key":"297_CR8","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1172\/JCI35180","volume":"118","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel L, et al. The anticancer immune response: indispensable for therapeutic success? J Clin Invest. 2008;118(6):1991\u20132001.","journal-title":"J Clin Invest"},{"issue":"6024","key":"297_CR9","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science. 2011;331(6024):1565\u201370.","journal-title":"Science"},{"key":"297_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1600-065X.2008.00649.x","volume":"224","author":"KS Peggs","year":"2008","unstructured":"Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev. 2008;224:141\u201365.","journal-title":"Immunol Rev"},{"issue":"9","key":"297_CR11","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1158\/1078-0432.CCR-15-1823","volume":"23","author":"YG Najjar","year":"2017","unstructured":"Najjar YG, et al. Myeloid-derived suppressor cell subset accumulation in renal cell carcinoma parenchyma is associated with intratumoral expression of IL1beta, IL8, CXCL5, and Mip-1alpha. Clin Cancer Res. 2017;23(9):2346\u201355.","journal-title":"Clin Cancer Res"},{"key":"297_CR12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3389\/fimmu.2014.00489","volume":"5","author":"D Laoui","year":"2014","unstructured":"Laoui D, et al. Functional relationship between tumor-associated macrophages and macrophage colony-stimulating factor as contributors to cancer progression. Front Immunol. 2014;5:489.","journal-title":"Front Immunol"},{"key":"297_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2013.12.005","volume":"27","author":"H Nishikawa","year":"2014","unstructured":"Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol. 2014;27:1\u20137.","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"297_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1586\/14737140.8.2.151","volume":"8","author":"K Mori","year":"2008","unstructured":"Mori K, Ando K, Heymann D. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases. Expert Rev Anticancer Ther. 2008;8(2):151\u20139.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"297_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1517\/14656566.2011.543129","volume":"12","author":"K Ando","year":"2011","unstructured":"Ando K, et al. Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother. 2011;12(2):285\u201392.","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"297_CR16","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1586\/era.09.69","volume":"9","author":"PA Meyers","year":"2009","unstructured":"Meyers PA. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther. 2009;9(8):1035\u201349.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"297_CR17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrd2783","volume":"8","author":"K Geddes","year":"2009","unstructured":"Geddes K, Magalhaes JG, Girardin SE. Unleashing the therapeutic potential of NOD-like receptors. Nat Rev Drug Discov. 2009;8(6):465\u201379.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"297_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2165\/11204910-000000000-00000","volume":"12","author":"JE Frampton","year":"2010","unstructured":"Frampton JE. Mifamurtide: a review of its use in the treatment of osteosarcoma. Paediatr Drugs. 2010;12(3):141\u201353.","journal-title":"Paediatr Drugs"},{"issue":"10","key":"297_CR19","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa0905680","volume":"362","author":"C Steidl","year":"2010","unstructured":"Steidl C, et al. Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma. N Engl J Med. 2010;362(10):875\u201385.","journal-title":"N Engl J Med"},{"issue":"2","key":"297_CR20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/pbc.24686","volume":"61","author":"PM Anderson","year":"2014","unstructured":"Anderson PM, et al. Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. Pediatr Blood Cancer. 2014;61(2):238\u201344.","journal-title":"Pediatr Blood Cancer"},{"issue":"22","key":"297_CR21","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1002\/cncr.24566","volume":"115","author":"AJ Chou","year":"2009","unstructured":"Chou AJ, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children\u2019s Oncology Group. Cancer. 2009;115(22):5339\u201348.","journal-title":"Cancer"},{"key":"297_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/TCRM.S5688","volume":"6","author":"L Kager","year":"2010","unstructured":"Kager L, Potschger U, Bielack S. Review of mifamurtide in the treatment of patients with osteosarcoma. Ther Clin Risk Manag. 2010;6:279\u201386.","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"297_CR23","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1200\/JCO.2008.14.0095","volume":"26","author":"PA Meyers","year":"2008","unstructured":"Meyers PA, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival\u2014a report from the Children\u2019s Oncology Group. J Clin Oncol. 2008;26(4):633\u20138.","journal-title":"J Clin Oncol"},{"issue":"8","key":"297_CR24","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1158\/1078-0432.CCR-10-2047","volume":"17","author":"EP Buddingh","year":"2011","unstructured":"Buddingh EP, et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res. 2011;17(8):2110\u20139.","journal-title":"Clin Cancer Res"},{"key":"297_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1756-9966-33-27","volume":"33","author":"JH Pahl","year":"2014","unstructured":"Pahl JH, et al. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-gamma. J Exp Clin Cancer Res. 2014;33:27.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"297_CR26","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/pbc.25983","volume":"63","author":"F Navid","year":"2016","unstructured":"Navid F, et al. Feasibility of pegylated interferon in children and young adults with resected high-risk melanoma. Pediatr Blood Cancer. 2016;63(7):1207\u201313.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"297_CR27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/02841860510029978","volume":"44","author":"CR Muller","year":"2005","unstructured":"Muller CR, et al. Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncol. 2005;44(5):475\u201380.","journal-title":"Acta Oncol"},{"issue":"6","key":"297_CR28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1200\/JCO.1984.2.6.617","volume":"2","author":"K Winkler","year":"1984","unstructured":"Winkler K, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German\/Austrian study. J Clin Oncol. 1984;2(6):617\u201324.","journal-title":"J Clin Oncol"},{"issue":"20","key":"297_CR29","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1200\/JCO.2014.60.0734","volume":"33","author":"SS Bielack","year":"2015","unstructured":"Bielack SS, et al. Methotrexate, Doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol. 2015;33(20):2279\u201387.","journal-title":"J Clin Oncol"},{"issue":"4862","key":"297_CR30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1126\/science.3260404","volume":"241","author":"JP Shaw","year":"1988","unstructured":"Shaw JP, et al. Identification of a putative regulator of early T cell activation genes. Science. 1988;241(4862):202\u20135.","journal-title":"Science"},{"issue":"12","key":"297_CR31","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1002\/1097-0142(19950615)75:12<2959::AID-CNCR2820751225>3.0.CO;2-R","volume":"75","author":"M Bauer","year":"1995","unstructured":"Bauer M, et al. A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin\u2019s lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study. Cancer. 1995;75(12):2959\u201365.","journal-title":"Cancer"},{"issue":"4","key":"297_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1089\/107999003765027375","volume":"23","author":"K Kalwak","year":"2003","unstructured":"Kalwak K, et al. Immunologic effects of intermediate-dose IL-2 i.v. after autologous hematopoietic cell transplantation in pediatric solid tumors. J Interferon Cytokine Res. 2003;23(4):173\u201381.","journal-title":"J Interferon Cytokine Res"},{"issue":"7","key":"297_CR33","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/annonc\/mdi226","volume":"16","author":"W Schwinger","year":"2005","unstructured":"Schwinger W, et al. Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients. Ann Oncol. 2005;16(7):1199\u2013206.","journal-title":"Ann Oncol"},{"issue":"10","key":"297_CR34","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.2217\/imt-2016-0048","volume":"8","author":"CK Lettieri","year":"2016","unstructured":"Lettieri CK, et al. Progress and opportunities for immune therapeutics in osteosarcoma. Immunotherapy. 2016;8(10):1233\u201344.","journal-title":"Immunotherapy"},{"issue":"4","key":"297_CR35","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ccell.2017.03.002","volume":"31","author":"RG Majzner","year":"2017","unstructured":"Majzner RG, Heitzeneder S, Mackall CL. Harnessing the immunotherapy revolution for the treatment of childhood cancers. Cancer Cell. 2017;31(4):476\u201385.","journal-title":"Cancer Cell"},{"issue":"15_suppl","key":"297_CR36","doi-asserted-by":"publisher","first-page":"10507","DOI":"10.1200\/JCO.2016.34.15_suppl.10507","volume":"34","author":"V Minard-Colin","year":"2016","unstructured":"Minard-Colin V, et al. Results of the randomized intergroup trial inter-B-NHL Ritux 2010 for children and adolescents with high risk B-cell non Hodgkin\u2019s lymphoma and mature acute leukemia: evaluation of rituximab efficacy in addition to standard LMB chemotherapy regimen. J Clin Oncol. 2016;34(15_suppl):10507.","journal-title":"J Clin Oncol"},{"issue":"18","key":"297_CR37","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30(18):2183\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"297_CR38","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00277-014-2218-6","volume":"94","author":"J Loke","year":"2015","unstructured":"Loke J, et al. Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. Ann Hematol. 2015;94(3):361\u201373.","journal-title":"Ann Hematol"},{"key":"297_CR39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.exphem.2017.06.007","volume":"54","author":"AA Laing","year":"2017","unstructured":"Laing AA, et al. Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia. Exp Hematol. 2017;54:40\u201350.","journal-title":"Exp Hematol"},{"issue":"4","key":"297_CR40","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","volume":"13","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403\u201311.","journal-title":"Lancet Oncol"},{"issue":"8","key":"297_CR41","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740\u201353.","journal-title":"N Engl J Med"},{"issue":"21","key":"297_CR42","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1056\/NEJMc1612040","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, Vandendries E, Advani AS. Inotuzumab ozogamicin for acute lymphoblastic leukemia. N Engl J Med. 2016;375(21):2100\u20131.","journal-title":"N Engl J Med"},{"issue":"9","key":"297_CR43","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347.","journal-title":"N Engl J Med"},{"issue":"36","key":"297_CR44","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","volume":"34","author":"A Stackelberg von","year":"2016","unstructured":"von Stackelberg A, et al. Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34(36):4381\u20139.","journal-title":"J Clin Oncol"},{"issue":"14","key":"297_CR45","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","volume":"363","author":"AL Yu","year":"2010","unstructured":"Yu AL, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324\u201334.","journal-title":"N Engl J Med"},{"issue":"33","key":"297_CR46","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.1200\/JCO.2009.27.8861","volume":"28","author":"S Shusterman","year":"2010","unstructured":"Shusterman S, et al. Antitumor activity of hu14.18-IL2 in patients with relapsed\/refractory neuroblastoma: a Children\u2019s Oncology Group (COG) phase II study. J Clin Oncol. 2010;28(33):4969\u201375.","journal-title":"J Clin Oncol"},{"issue":"20","key":"297_CR47","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1200\/JCO.2011.37.4546","volume":"30","author":"D Ebb","year":"2012","unstructured":"Ebb D, et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children\u2019s oncology group. J Clin Oncol. 2012;30(20):2545\u201351.","journal-title":"J Clin Oncol"},{"issue":"3","key":"297_CR48","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/pbc.24605","volume":"61","author":"B Weigel","year":"2014","unstructured":"Weigel B, et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2014;61(3):452\u20136.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"297_CR49","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1200\/JCO.2011.37.4355","volume":"30","author":"S Malempati","year":"2012","unstructured":"Malempati S, et al. Phase I\/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2012;30(3):256\u201362.","journal-title":"J Clin Oncol"},{"issue":"20","key":"297_CR50","first-page":"5377","volume":"47","author":"JP Heiner","year":"1987","unstructured":"Heiner JP, et al. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res. 1987;47(20):5377\u201381.","journal-title":"Cancer Res"},{"issue":"4","key":"297_CR51","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s00262-004-0603-z","volume":"54","author":"M Wolfl","year":"2005","unstructured":"Wolfl M, et al. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother. 2005;54(4):400\u20136.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"297_CR52","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/jcp.10290","volume":"195","author":"A Garcia-Lora","year":"2003","unstructured":"Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol. 2003;195(3):346\u201355.","journal-title":"J Cell Physiol"},{"issue":"8","key":"297_CR53","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725\u201333.","journal-title":"N Engl J Med"},{"issue":"18","key":"297_CR54","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens RJ, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817\u201328.","journal-title":"Blood"},{"issue":"9967","key":"297_CR55","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517\u201328.","journal-title":"Lancet"},{"issue":"16","key":"297_CR56","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317.","journal-title":"N Engl J Med"},{"issue":"16","key":"297_CR57","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509\u201318.","journal-title":"N Engl J Med"},{"issue":"7","key":"297_CR58","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","volume":"121","author":"W Haso","year":"2013","unstructured":"Haso W, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121(7):1165\u201374.","journal-title":"Blood"},{"issue":"14","key":"297_CR59","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2017-02-749101","volume":"130","author":"AS Wayne","year":"2017","unstructured":"Wayne AS, et al. Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. Blood. 2017;130(14):1620\u20137.","journal-title":"Blood"},{"issue":"25","key":"297_CR60","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","volume":"113","author":"A Stasi Di","year":"2009","unstructured":"Di Stasi A, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009;113(25):6392\u2013402.","journal-title":"Blood"},{"issue":"5","key":"297_CR61","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1182\/blood-2014-11-612903","volume":"126","author":"H Qin","year":"2015","unstructured":"Qin H, et al. Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood. 2015;126(5):629\u201339.","journal-title":"Blood"},{"issue":"10","key":"297_CR62","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1172\/JCI87366","volume":"126","author":"M Ruella","year":"2016","unstructured":"Ruella M, et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016;126(10):3814\u201326.","journal-title":"J Clin Invest"},{"issue":"23","key":"297_CR63","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","volume":"118","author":"CU Louis","year":"2011","unstructured":"Louis CU, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118(23):6050\u20136.","journal-title":"Blood"},{"issue":"4","key":"297_CR64","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843\u201351.","journal-title":"Mol Ther"},{"issue":"15","key":"297_CR65","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","volume":"33","author":"N Ahmed","year":"2015","unstructured":"Ahmed N, et al. Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol. 2015;33(15):1688\u201396.","journal-title":"J Clin Oncol"},{"issue":"24","key":"297_CR66","doi-asserted-by":"publisher","first-page":"9160","DOI":"10.1158\/0008-5472.CAN-04-0454","volume":"64","author":"KS Kahlon","year":"2004","unstructured":"Kahlon KS, et al. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 2004;64(24):9160\u20136.","journal-title":"Cancer Res"},{"issue":"10","key":"297_CR67","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1089\/hum.2012.041","volume":"23","author":"RA Morgan","year":"2012","unstructured":"Morgan RA, et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther. 2012;23(10):1043\u201353.","journal-title":"Hum Gene Ther"},{"issue":"7","key":"297_CR68","doi-asserted-by":"publisher","first-page":"e0133152","DOI":"10.1371\/journal.pone.0133152","volume":"10","author":"X Huang","year":"2015","unstructured":"Huang X, et al. IGF1R- and ROR1-specific CAR T cells as a potential therapy for high risk sarcomas. PLoS One. 2015;10(7):e0133152.","journal-title":"PLoS One"},{"issue":"2","key":"297_CR69","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/eji.1830050209","volume":"5","author":"R Kiessling","year":"1975","unstructured":"Kiessling R, et al. \u201cNatural\u201d killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol. 1975;5(2):117\u201321.","journal-title":"Eur J Immunol"},{"issue":"15","key":"297_CR70","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1056\/NEJM198704093161501","volume":"316","author":"SA Rosenberg","year":"1987","unstructured":"Rosenberg SA, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316(15):889\u201397.","journal-title":"N Engl J Med"},{"issue":"8","key":"297_CR71","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller JS, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051\u20137.","journal-title":"Blood"},{"issue":"6","key":"297_CR72","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","volume":"28","author":"JE Rubnitz","year":"2010","unstructured":"Rubnitz JE, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010;28(6):955\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"297_CR73","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3109\/14653249.2010.515582","volume":"13","author":"MA Geller","year":"2011","unstructured":"Geller MA, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13(1):98\u2013107.","journal-title":"Cytotherapy"},{"issue":"12","key":"297_CR74","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s00262-010-0904-3","volume":"59","author":"EG Iliopoulou","year":"2010","unstructured":"Iliopoulou EG, et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother. 2010;59(12):1781\u20139.","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"297_CR75","doi-asserted-by":"publisher","first-page":"882.e1","DOI":"10.1016\/j.exphem.2012.07.004","volume":"40","author":"A Perez-Martinez","year":"2012","unstructured":"Perez-Martinez A, et al. Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. Exp Hematol. 2012;40(11):882.e1\u2013891.e1.","journal-title":"Exp Hematol"},{"issue":"1","key":"297_CR76","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/pbc.21955","volume":"53","author":"A Perez-Martinez","year":"2009","unstructured":"Perez-Martinez A, et al. KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. Pediatr Blood Cancer. 2009;53(1):120\u20134.","journal-title":"Pediatr Blood Cancer"},{"key":"297_CR77","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3389\/fonc.2017.00136","volume":"7","author":"J Yin","year":"2017","unstructured":"Yin J, Markert JM, Leavenworth JW. Modulation of the intratumoral immune landscape by oncolytic herpes simplex virus virotherapy. Front Oncol. 2017;7:136.","journal-title":"Front Oncol"},{"issue":"7","key":"297_CR78","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2217\/imt-2016-0002","volume":"8","author":"C Kyi","year":"2016","unstructured":"Kyi C, Postow MA. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy. 2016;8(7):821\u201337.","journal-title":"Immunotherapy"},{"issue":"25","key":"297_CR79","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"297_CR80","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/gt.2015.105","volume":"23","author":"PY Wang","year":"2016","unstructured":"Wang PY, et al. Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility. Gene Ther. 2016;23(2):135\u201343.","journal-title":"Gene Ther"},{"issue":"2","key":"297_CR81","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/pbc.22535","volume":"55","author":"CL Morton","year":"2010","unstructured":"Morton CL, et al. Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010;55(2):295\u2013303.","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"297_CR82","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/cncr.25741","volume":"117","author":"P Hingorani","year":"2011","unstructured":"Hingorani P, et al. Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts. Cancer. 2011;117(8):1764\u201374.","journal-title":"Cancer"},{"issue":"5","key":"297_CR83","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.molonc.2013.05.004","volume":"7","author":"X Lun","year":"2013","unstructured":"Lun X, et al. Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors. Mol Oncol. 2013;7(5):944\u201354.","journal-title":"Mol Oncol"},{"issue":"14","key":"297_CR84","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.1158\/1078-0432.CCR-16-2900","volume":"23","author":"KA Streby","year":"2017","unstructured":"Streby KA, et al. Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients. Clin Cancer Res. 2017;23(14):3566\u201374.","journal-title":"Clin Cancer Res"},{"issue":"22","key":"297_CR85","doi-asserted-by":"publisher","first-page":"5564","DOI":"10.1158\/1078-0432.CCR-10-1233","volume":"16","author":"C Comins","year":"2010","unstructured":"Comins C, et al. REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res. 2010;16(22):5564\u201372.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"297_CR86","doi-asserted-by":"publisher","first-page":"7127","DOI":"10.1158\/1078-0432.CCR-08-0524","volume":"14","author":"L Vidal","year":"2008","unstructured":"Vidal L, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res. 2008;14(21):7127\u201337.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"297_CR87","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/mt.2014.243","volume":"23","author":"TP Cripe","year":"2015","unstructured":"Cripe TP, et al. Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. Mol Ther. 2015;23(3):602\u20138.","journal-title":"Mol Ther"},{"issue":"1","key":"297_CR88","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1038\/s41598-017-02503-8","volume":"7","author":"CY Chen","year":"2017","unstructured":"Chen CY, et al. Cooperation of oncolytic herpes virotherapy and PD-1 blockade in murine rhabdomyosarcoma models. Sci Rep. 2017;7(1):2396.","journal-title":"Sci Rep"},{"key":"297_CR89","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.omto.2017.09.001","volume":"7","author":"B Hutzen","year":"2017","unstructured":"Hutzen B, et al. TGF-beta inhibition improves oncolytic herpes viroimmunotherapy in murine models of rhabdomyosarcoma. Mol Ther Oncolytics. 2017;7:17\u201326.","journal-title":"Mol Ther Oncolytics"},{"key":"297_CR90","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fonc.2017.00114","volume":"7","author":"DE Meyers","year":"2017","unstructured":"Meyers DE, et al. Current immunotherapeutic strategies to enhance oncolytic virotherapy. Front Oncol. 2017;7:114.","journal-title":"Front Oncol"},{"issue":"51","key":"297_CR91","doi-asserted-by":"publisher","first-page":"7377","DOI":"10.1016\/j.vaccine.2015.10.057","volume":"33","author":"MA Morse","year":"2015","unstructured":"Morse MA, Lyerly HK. Checkpoint blockade in combination with cancer vaccines. Vaccine. 2015;33(51):7377\u201385.","journal-title":"Vaccine"},{"key":"297_CR92","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.2147\/OTT.S124008","volume":"10","author":"LM Wagner","year":"2017","unstructured":"Wagner LM, Adams VR. Targeting the PD-1 pathway in pediatric solid tumors and brain tumors. Onco Targets Ther. 2017;10:2097\u2013106.","journal-title":"Onco Targets Ther"},{"issue":"17","key":"297_CR93","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974\u201382.","journal-title":"J Clin Oncol"},{"issue":"2","key":"297_CR94","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123\u201335.","journal-title":"N Engl J Med"},{"issue":"4","key":"297_CR95","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372(4):311\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"297_CR96","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.eururo.2015.03.022","volume":"68","author":"T Powles","year":"2015","unstructured":"Powles T. Immune checkpoint inhibitors for urologic cancer: the tip of the iceberg? Eur Urol. 2015;68(2):280\u20132.","journal-title":"Eur Urol"},{"issue":"4","key":"297_CR97","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450\u201361.","journal-title":"Cancer Cell"},{"issue":"1","key":"297_CR98","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1073\/pnas.1016791108","volume":"108","author":"VA Pedicord","year":"2011","unstructured":"Pedicord VA, et al. Single dose of anti-CTLA-4 enhances CD8\u2009+\u2009T-cell memory formation, function, and maintenance. Proc Natl Acad Sci USA. 2011;108(1):266\u201371.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"297_CR99","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1073\/pnas.0910341107","volume":"107","author":"N Jain","year":"2010","unstructured":"Jain N, et al. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl Acad Sci USA. 2010;107(4):1524\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"297_CR100","first-page":"385","volume":"4","author":"MK Callahan","year":"2014","unstructured":"Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 pathway blockade: combinations in the clinic. Front Oncol. 2014;4:385.","journal-title":"Front Oncol"},{"key":"297_CR101","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev.iy.11.040193.001203","volume":"11","author":"PS Linsley","year":"1993","unstructured":"Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol. 1993;11:191\u2013212.","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"297_CR102","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/0167-5699(94)90080-9","volume":"15","author":"CH June","year":"1994","unstructured":"June CH, et al. The B7 and CD28 receptor families. Immunol Today. 1994;15(7):321\u201331.","journal-title":"Immunol Today"},{"issue":"4","key":"297_CR103","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1073\/pnas.86.4.1333","volume":"86","author":"CB Thompson","year":"1989","unstructured":"Thompson CB, et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines\/cytokines. Proc Natl Acad Sci USA. 1989;86(4):1333\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5256","key":"297_CR104","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734\u20136.","journal-title":"Science"},{"issue":"2","key":"297_CR105","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","volume":"11","author":"JD Wolchok","year":"2010","unstructured":"Wolchok JD, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155\u201364.","journal-title":"Lancet Oncol"},{"key":"297_CR106","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40425-015-0082-0","volume":"3","author":"P Hingorani","year":"2015","unstructured":"Hingorani P, et al. Increased CTLA-4(+) T cells and an increased ratio of monocytes with loss of class II (CD14(+) HLA-DR(lo\/neg)) found in aggressive pediatric sarcoma patients. J Immunother Cancer. 2015;3:35.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"297_CR107","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/ijc.21155","volume":"117","author":"E Contardi","year":"2005","unstructured":"Contardi E, et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer. 2005;117(4):538\u201350.","journal-title":"Int J Cancer"},{"issue":"6","key":"297_CR108","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1158\/1078-0432.CCR-15-0491","volume":"22","author":"MS Merchant","year":"2016","unstructured":"Merchant MS, et al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res. 2016;22(6):1364\u201370.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"297_CR109","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","volume":"36","author":"KE Pauken","year":"2015","unstructured":"Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36(4):265\u201376.","journal-title":"Trends Immunol"},{"issue":"5","key":"297_CR110","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.immuni.2014.10.013","volume":"41","author":"MM Staron","year":"2014","unstructured":"Staron MM, et al. The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. Immunity. 2014;41(5):802\u201314.","journal-title":"Immunity"},{"issue":"11","key":"297_CR111","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1080\/13543784.2016.1237503","volume":"25","author":"MF Heymann","year":"2016","unstructured":"Heymann MF, Brown HK, Heymann D. Drugs in early clinical development for the treatment of osteosarcoma. Expert Opin Investig Drugs. 2016;25(11):1265\u201380.","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"297_CR112","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/CJI.0000000000000065","volume":"38","author":"DM Lussier","year":"2015","unstructured":"Lussier DM, et al. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1\/PD-L1 interactions. J Immunother. 2015;38(3):96\u2013106.","journal-title":"J Immunother"},{"issue":"8","key":"297_CR113","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12032-016-0807-z","volume":"33","author":"S Paydas","year":"2016","unstructured":"Paydas S, et al. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas. Med Oncol. 2016;33(8):93.","journal-title":"Med Oncol"},{"key":"297_CR114","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s12885-016-2451-6","volume":"16","author":"C Kim","year":"2016","unstructured":"Kim C, et al. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer. 2016;16:434.","journal-title":"BMC Cancer"},{"issue":"8","key":"297_CR115","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1097\/PAS.0000000000000653","volume":"40","author":"S Inaguma","year":"2016","unstructured":"Inaguma S, et al. Comprehensive immunohistochemical study of programmed cell death ligand 1 (PD-L1): analysis in 5536 cases revealed consistent expression in trophoblastic tumors. Am J Surg Pathol. 2016;40(8):1133\u201342.","journal-title":"Am J Surg Pathol"},{"issue":"41","key":"297_CR116","doi-asserted-by":"crossref","first-page":"71371","DOI":"10.18632\/oncotarget.19071","volume":"8","author":"AEM Erp van","year":"2017","unstructured":"van Erp AEM, et al. Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8(+) lymphocytes in primary sarcomas is subtype dependent. Oncotarget. 2017;8(41):71371\u201384.","journal-title":"Oncotarget"},{"issue":"19","key":"297_CR117","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1002\/cncr.30724","volume":"123","author":"RG Majzner","year":"2017","unstructured":"Majzner RG, et al. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. Cancer. 2017;123(19):3807\u201315.","journal-title":"Cancer"},{"issue":"15_suppl","key":"297_CR118","doi-asserted-by":"publisher","first-page":"10525","DOI":"10.1200\/JCO.2017.35.15_suppl.10525","volume":"35","author":"B Geoerger","year":"2017","unstructured":"Geoerger B, et al. Phase 1\/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1 + advanced, relapsed, or refractory solid tumor or lymphoma. J Clin Oncol. 2017;35(15_suppl):10525.","journal-title":"J Clin Oncol"},{"issue":"11","key":"297_CR119","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493\u2013501.","journal-title":"Lancet Oncol"},{"issue":"19","key":"297_CR120","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125\u201332.","journal-title":"J Clin Oncol"},{"key":"297_CR121","unstructured":"Pembrolizumab (KEYTRUDA) for classical Hodgkin lymphoma. 2017 3\/15\/2017 [cited 2018 April 30]. https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm546893.htm . Accessed 30 Apr 2018."},{"issue":"5","key":"297_CR122","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/eji.1830260533","volume":"26","author":"B Huard","year":"1996","unstructured":"Huard B, et al. T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding. Eur J Immunol. 1996;26(5):1180\u20136.","journal-title":"Eur J Immunol"},{"issue":"1","key":"297_CR123","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1517\/14712598.2011.540563","volume":"15","author":"S Sierro","year":"2011","unstructured":"Sierro S, Romero P, Speiser DE. The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets. 2011;15(1):91\u2013101.","journal-title":"Expert Opin Ther Targets"},{"issue":"11","key":"297_CR124","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/ni987","volume":"4","author":"A Sanchez-Fueyo","year":"2003","unstructured":"Sanchez-Fueyo A, et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol. 2003;4(11):1093\u2013101.","journal-title":"Nat Immunol"},{"issue":"4","key":"297_CR125","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"297_CR126","doi-asserted-by":"publisher","first-page":"e27817","DOI":"10.4161\/onci.27817","volume":"3","author":"S Champiat","year":"2014","unstructured":"Champiat S, et al. Exomics and immunogenics: bridging mutational load and immune checkpoints efficacy. Oncoimmunology. 2014;3(1):e27817.","journal-title":"Oncoimmunology"},{"issue":"11","key":"297_CR127","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/nrc3838","volume":"14","author":"M Kansara","year":"2014","unstructured":"Kansara M, et al. Translational biology of osteosarcoma. Nat Rev Cancer. 2014;14(11):722\u201335.","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"297_CR128","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189\u201399.","journal-title":"N Engl J Med"},{"issue":"8","key":"297_CR129","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMc1415938","volume":"372","author":"A Snyder","year":"2015","unstructured":"Snyder A, Wolchok JD, Chan TA. Genetic basis for clinical response to CTLA-4 blockade. N Engl J Med. 2015;372(8):783.","journal-title":"N Engl J Med"},{"issue":"6230","key":"297_CR130","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124\u20138.","journal-title":"Science"},{"issue":"7528","key":"297_CR131","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563\u20137.","journal-title":"Nature"},{"issue":"26","key":"297_CR132","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509\u201320.","journal-title":"N Engl J Med"},{"issue":"7457","key":"297_CR133","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214\u20138.","journal-title":"Nature"},{"issue":"3","key":"297_CR134","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/ng.3202","volume":"47","author":"A Shlien","year":"2015","unstructured":"Shlien A, et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet. 2015;47(3):257\u201362.","journal-title":"Nat Genet"},{"key":"297_CR135","doi-asserted-by":"publisher","first-page":"675269","DOI":"10.1155\/2015\/675269","volume":"2015","author":"MA Huang","year":"2015","unstructured":"Huang MA, Krishnadas DK, Lucas KG. Cellular and antibody based approaches for pediatric cancer immunotherapy. J Immunol Res. 2015;2015:675269.","journal-title":"J Immunol Res"},{"issue":"9","key":"297_CR136","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.2217\/fon.14.62","volume":"10","author":"CM Capitini","year":"2014","unstructured":"Capitini CM, et al. Immunotherapy in pediatric malignancies: current status and future perspectives. Future Oncol. 2014;10(9):1659\u201378.","journal-title":"Future Oncol"},{"issue":"2","key":"297_CR137","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/bjc.1996.28","volume":"73","author":"P Korkolopoulou","year":"1996","unstructured":"Korkolopoulou P, et al. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer. 1996;73(2):148\u201353.","journal-title":"Br J Cancer"},{"key":"297_CR138","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40425-015-0067-z","volume":"3","author":"DM Lussier","year":"2015","unstructured":"Lussier DM, et al. Combination immunotherapy with alpha-CTLA-4 and alpha-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J Immunother Cancer. 2015;3:21.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"297_CR139","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122\u201333.","journal-title":"N Engl J Med"},{"issue":"1","key":"297_CR140","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med"},{"issue":"1","key":"297_CR141","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00262-016-1925-3","volume":"66","author":"YT Sundara","year":"2017","unstructured":"Sundara YT, et al. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunol Immunother. 2017;66(1):119\u201328.","journal-title":"Cancer Immunol Immunother"},{"key":"297_CR142","doi-asserted-by":"publisher","first-page":"30093","DOI":"10.1038\/srep30093","volume":"6","author":"P Koirala","year":"2016","unstructured":"Koirala P, et al. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep. 2016;6:30093.","journal-title":"Sci Rep"},{"issue":"8","key":"297_CR143","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/pbc.26018","volume":"63","author":"T Aoki","year":"2016","unstructured":"Aoki T, et al. Low frequency of programmed death ligand 1 expression in pediatric cancers. Pediatr Blood Cancer. 2016;63(8):1461\u20134.","journal-title":"Pediatr Blood Cancer"},{"issue":"7629","key":"297_CR144","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature20554","volume":"539","author":"O Henau De","year":"2016","unstructured":"De Henau O, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells. Nature. 2016;539(7629):443\u20137.","journal-title":"Nature"},{"key":"297_CR145","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fonc.2016.00233","volume":"6","author":"M Swart","year":"2016","unstructured":"Swart M, Verbrugge I, Beltman JB. Combination approaches with immune-checkpoint blockade in cancer therapy. Front Oncol. 2016;6:233.","journal-title":"Front Oncol"},{"key":"297_CR146","first-page":"391967","volume":"2014","author":"SP D\u2019Angelo","year":"2014","unstructured":"D\u2019Angelo SP, et al. Sarcoma immunotherapy: past approaches and future directions. Sarcoma. 2014;2014:391967.","journal-title":"Sarcoma"},{"key":"297_CR147","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ctrv.2017.05.006","volume":"58","author":"JA Park","year":"2017","unstructured":"Park JA, Cheung NV. Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. Cancer Treat Rev. 2017;58:22\u201333.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"297_CR148","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00262-012-1317-2","volume":"62","author":"NA Sheikh","year":"2013","unstructured":"Sheikh NA, et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother. 2013;62(1):137\u201347.","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"297_CR149","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/nm.2883","volume":"18","author":"S Walter","year":"2012","unstructured":"Walter S, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012;18(8):1254\u201361.","journal-title":"Nat Med"},{"issue":"15","key":"297_CR150","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1158\/0008-5472.CAN-13-2685","volume":"74","author":"J Fu","year":"2014","unstructured":"Fu J, et al. Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res. 2014;74(15):4042\u201352.","journal-title":"Cancer Res"},{"issue":"1","key":"297_CR151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000062","volume":"38","author":"KC Soares","year":"2015","unstructured":"Soares KC, et al. PD-1\/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother. 2015;38(1):1\u201311.","journal-title":"J Immunother"},{"issue":"17","key":"297_CR152","doi-asserted-by":"publisher","first-page":"10067","DOI":"10.1073\/pnas.95.17.10067","volume":"95","author":"AA Hurwitz","year":"1998","unstructured":"Hurwitz AA, et al. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA. 1998;95(17):10067\u201371.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"297_CR153","first-page":"2444","volume":"60","author":"AA Hurwitz","year":"2000","unstructured":"Hurwitz AA, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 2000;60(9):2444\u20138.","journal-title":"Cancer Res"},{"issue":"13","key":"297_CR154","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1158\/1078-0432.CCR-12-3226","volume":"19","author":"EL Williams","year":"2013","unstructured":"Williams EL, et al. Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model. Clin Cancer Res. 2013;19(13):3545\u201355.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"297_CR155","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1002\/eji.201041235","volume":"41","author":"SR Sierro","year":"2011","unstructured":"Sierro SR, et al. Combination of lentivector immunization and low-dose chemotherapy or PD-1\/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur J Immunol. 2011;41(8):2217\u201328.","journal-title":"Eur J Immunol"},{"issue":"26","key":"297_CR156","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1182\/blood-2015-12-629089","volume":"127","author":"C Sun","year":"2016","unstructured":"Sun C, Dotti G, Savoldo B. Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies. Blood. 2016;127(26):3350\u20139.","journal-title":"Blood"},{"issue":"22","key":"297_CR157","doi-asserted-by":"publisher","first-page":"6151","DOI":"10.1158\/1078-0432.CCR-13-1189","volume":"19","author":"A Morales-Kastresana","year":"2013","unstructured":"Morales-Kastresana A, et al. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res. 2013;19(22):6151\u201362.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"297_CR158","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/annonc\/mdt107","volume":"24","author":"SF Slovin","year":"2013","unstructured":"Slovin SF, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I\/II study. Ann Oncol. 2013;24(7):1813\u201321.","journal-title":"Ann Oncol"},{"issue":"3","key":"297_CR159","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3892\/ol.2013.1118","volume":"5","author":"X Zhao","year":"2013","unstructured":"Zhao X, et al. Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma. Oncol Lett. 2013;5(3):805\u201312.","journal-title":"Oncol Lett"},{"issue":"2","key":"297_CR160","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3171\/2016.8.PEDS16326","volume":"19","author":"X Zhu","year":"2017","unstructured":"Zhu X, et al. Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report. J Neurosurg Pediatr. 2017;19(2):249\u201353.","journal-title":"J Neurosurg Pediatr"},{"issue":"3","key":"297_CR161","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nrclinonc.2010.223","volume":"8","author":"L Zitvogel","year":"2011","unstructured":"Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011;8(3):151\u201360.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"297_CR162","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1084\/jem.20121416","volume":"210","author":"BH Zinselmeyer","year":"2013","unstructured":"Zinselmeyer BH, et al. PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J Exp Med. 2013;210(4):757\u201374.","journal-title":"J Exp Med"},{"issue":"2","key":"297_CR163","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/leu.2015.214","volume":"30","author":"C Krupka","year":"2016","unstructured":"Krupka C, et al. Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia. 2016;30(2):484\u201391.","journal-title":"Leukemia"},{"issue":"12","key":"297_CR164","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17(12):e542\u201351.","journal-title":"Lancet Oncol"},{"issue":"5","key":"297_CR165","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275\u201387.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"297_CR166","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015;14(4):847\u201356.","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"297_CR167","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"key":"297_CR168","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.critrevonc.2017.06.001","volume":"116","author":"S Maleki Vareki","year":"2017","unstructured":"Maleki Vareki S, Garrigos C, Duran I. Biomarkers of response to PD-1\/PD-L1 inhibition. Crit Rev Oncol Hematol. 2017;116:116\u201324.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"297_CR169","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","volume":"17","author":"SJ Antonia","year":"2016","unstructured":"Antonia SJ, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial. Lancet Oncol. 2016;17(7):883\u201395.","journal-title":"Lancet Oncol"},{"issue":"21","key":"297_CR170","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006\u201317.","journal-title":"N Engl J Med"},{"issue":"9","key":"297_CR171","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40265-016-0588-x","volume":"76","author":"L Festino","year":"2016","unstructured":"Festino L, et al. Cancer treatment with anti-PD-1\/PD-L1 agents: is PD-L1 expression a biomarker for patient selection? Drugs. 2016;76(9):925\u201345.","journal-title":"Drugs"},{"issue":"10","key":"297_CR172","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1158\/2326-6066.CIR-15-0043","volume":"3","author":"M Callea","year":"2015","unstructured":"Callea M, et al. Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma. Cancer Immunol Res. 2015;3(10):1158\u201364.","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"297_CR173","doi-asserted-by":"publisher","first-page":"e985930","DOI":"10.4161\/2162402X.2014.985930","volume":"4","author":"S Adams","year":"2015","unstructured":"Adams S, et al. Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). Oncoimmunology. 2015;4(9):e985930.","journal-title":"Oncoimmunology"},{"issue":"9","key":"297_CR174","doi-asserted-by":"publisher","first-page":"e1019981","DOI":"10.1080\/2162402X.2015.1019981","volume":"4","author":"M Mina","year":"2015","unstructured":"Mina M, et al. Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma. Oncoimmunology. 2015;4(9):e1019981.","journal-title":"Oncoimmunology"},{"issue":"3","key":"297_CR175","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/1078-0432.CCR-15-1543","volume":"22","author":"M Vassilakopoulou","year":"2016","unstructured":"Vassilakopoulou M, et al. Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma. Clin Cancer Res. 2016;22(3):704\u201313.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"297_CR176","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/path.2819","volume":"223","author":"D Berghuis","year":"2011","unstructured":"Berghuis D, et al. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J Pathol. 2011;223(3):347\u201357.","journal-title":"J Pathol"},{"issue":"12","key":"297_CR177","doi-asserted-by":"publisher","first-page":"e82870","DOI":"10.1371\/journal.pone.0082870","volume":"8","author":"JR Kim","year":"2013","unstructured":"Kim JR, et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One. 2013;8(12):e82870.","journal-title":"PLoS One"},{"issue":"10","key":"297_CR178","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/ijc.28581","volume":"134","author":"H Fujii","year":"2014","unstructured":"Fujii H, et al. CD8(+) tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma. Int J Cancer. 2014;134(10):2393\u2013402.","journal-title":"Int J Cancer"},{"key":"297_CR179","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/978-1-62703-727-3_16","volume":"1102","author":"T Schatton","year":"2014","unstructured":"Schatton T, et al. Tumor-infiltrating lymphocytes and their significance in melanoma prognosis. Methods Mol Biol. 2014;1102:287\u2013324.","journal-title":"Methods Mol Biol"},{"key":"297_CR180","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","volume":"4","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016;4:59.","journal-title":"J Immunother Cancer"},{"issue":"27","key":"297_CR181","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1200\/JCO.2007.15.0284","volume":"26","author":"MC Dieu-Nosjean","year":"2008","unstructured":"Dieu-Nosjean MC, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26(27):4410\u20137.","journal-title":"J Clin Oncol"},{"issue":"3","key":"297_CR182","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ccell.2016.02.004","volume":"29","author":"H Tang","year":"2016","unstructured":"Tang H, et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell. 2016;29(3):285\u201396.","journal-title":"Cancer Cell"},{"issue":"17","key":"297_CR183","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627\u201339.","journal-title":"N Engl J Med"},{"issue":"26","key":"297_CR184","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517\u201326.","journal-title":"N Engl J Med"},{"issue":"17","key":"297_CR185","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever MA, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323\u201337.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"297_CR186","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/MOP.0b013e3283350d3e","volume":"22","author":"AS Wayne","year":"2010","unstructured":"Wayne AS, Capitini CM, Mackall CL. Immunotherapy of childhood cancer: from biologic understanding to clinical application. Curr Opin Pediatr. 2010;22(1):2\u201311.","journal-title":"Curr Opin Pediatr"},{"issue":"5796","key":"297_CR187","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan RA, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126\u20139.","journal-title":"Science"},{"issue":"9","key":"297_CR188","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/mt.2014.148","volume":"22","author":"J Corrigan-Curay","year":"2014","unstructured":"Corrigan-Curay J, et al. T-cell immunotherapy: looking forward. Mol Ther. 2014;22(9):1564\u201374.","journal-title":"Mol Ther"},{"issue":"1","key":"297_CR189","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57\u201366.","journal-title":"Lancet Oncol"},{"issue":"8","key":"297_CR190","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"4","key":"297_CR191","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.clon.2016.11.007","volume":"29","author":"O Abdel-Rahman","year":"2017","unstructured":"Abdel-Rahman O, et al. Treatment-related death in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Clin Oncol (R Coll Radiol). 2017;29(4):218\u201330.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"25","key":"297_CR192","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","volume":"23","author":"P Attia","year":"2005","unstructured":"Attia P, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23(25):6043\u201353.","journal-title":"J Clin Oncol"},{"issue":"8","key":"297_CR193","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","volume":"30","author":"JC Yang","year":"2007","unstructured":"Yang JC, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825\u201330.","journal-title":"J Immunother"},{"issue":"6","key":"297_CR194","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1634\/theoncologist.2012-0483","volume":"18","author":"LA Fecher","year":"2013","unstructured":"Fecher LA, et al. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist. 2013;18(6):733\u201343.","journal-title":"Oncologist"},{"issue":"7","key":"297_CR195","doi-asserted-by":"publisher","first-page":"e0160221","DOI":"10.1371\/journal.pone.0160221","volume":"11","author":"N Abdel-Wahab","year":"2016","unstructured":"Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One. 2016;11(7):e0160221.","journal-title":"PLoS One"},{"key":"297_CR196","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40425-016-0134-0","volume":"4","author":"M Nishino","year":"2016","unstructured":"Nishino M. Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a \u201ccommon language\u201d for the new arena of cancer treatment. J Immunother Cancer. 2016;4:30.","journal-title":"J Immunother Cancer"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-018-0297-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-018-0297-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-018-0297-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T14:03:51Z","timestamp":1661436231000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-018-0297-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,12]]},"references-count":196,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["297"],"URL":"https:\/\/doi.org\/10.1007\/s40272-018-0297-x","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,12]]},"assertion":[{"value":"12 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mary Frances Wedekind, Nick Denton, Chun-Yu Chen, and Timothy Cripe declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}